Archived Webinar: An Introduction to the Pathogenesis of HIV Infection and Core Principles of Treatment
An Introduction to the Pathogenesis of HIV Infection and Core Principles of Treatment
Michael S. Saag, MD, and David H. Spach, MD
Release date: May 31, 2018
Expiration date: May 31, 2019
CME Credit Available: No longer available for CME credit
Assessment of Needs
The IAS–USA offers this introductory activity on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians. This 2-part webinar is designed for HIV or infectious disease fellows, residents, and practitioners who are new to the field of HIV research and management. It will describe the core principles of HIV management, including epidemiology, mechanisms of action of existing drugs, initial antiretroviral regimens, and drug resistance. This webinar will also be useful to experienced clinicians who seek a review of these core principles.
Upon completion of this webinar, learners will be able to:
- List key epidemiologic features of the HIV in the United States
Summarize the key steps in the HIV life cycle
Describe the mechanism of action of major classes of antiretroviral medications
- Select antiretroviral therapy in patients who are:
- Starting initial therapy
- Persistently low-level viremic
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research.
This activity is also relevant for registered nurses, PharmDs, and other health professionals.
Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, Merck, Proteus, and ViiV Healthcare. He has served as a consultant for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck, and ViiV Healthcare. (Updated 05/24/18)
Dr Spach has no relevant financial affiliations to disclose. He does not receive any honoraria for the activity. (Updated 5/29/18)
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.
How to Watch the Webinar
- Watch the webinar here.